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1. Summary 
1.1 Summary 
Basis of this work was the development of a new vaccine for the protection of chickens 
against infectious laryngotracheitis (ILT), which is caused by the infectious laryngotracheitis 
virus (ILTV). For this purpose, virus-like particles (VLPs) displaying particular glycoproteins 
of ILTV were generated.  
 
In Switzerland, ILT is among the notifiable diseases and immunization is not permitted. Live 
attenuated vaccines pose a certain risk of mutating or recombining with field strains resulting 
in new pathogenic variants. Furthermore, it is hard to differ between vaccine- and field-
strains. In contrast, VLPs are neither infectious nor replication competent and they offer the 
opportunity to present antigens in high density at their surface and thereby evoke an immune 
response. 
 
In this work, VLPs based on the murine leukemia virus (MLV) were used. The ILTV 
glycoproteins gB, gC, gD, and gJ were fused to the transmembrane domain of the epidermal 
growth factor receptor. This allows the incorporation into the plasma membrane and thus the 
presentation at the particle surface. The VLPs were generated via transfection of two 
expression vectors (1. ILTV glycoprotein, 2. MLV gag) into 293T cells and various 
techniques for their characterization were established.  
 
Further work will show, whether the developed VLPs confer a robust protection against ILTV 
infection.  
 
Keywords:  Virus-like particle, infectious laryngotracheitis, Vaccine 
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1.2 Zusammenfassung 
 Basis dieser Arbeit war die Entwicklung eines neuen Impfstoffs zum Schutz gegen die 
infektiöse Laryngotracheitis (ILT) beim Huhn, die durch das infektiöses Laryngotracheitis 
Virus (ILTV) verursacht wird. Dazu wurden pseudotypisierte virusähnliche Partikel 
hergestellt (VÄP), die auf ihrer Oberfläche ein bestimmtes Glykoprotein des ILTV  tragen.  
 
In der Schweiz ist ILT eine meldepflichtige Erkrankung und das Impfen ist verboten. Bei 
attenuierten Lebendimpfstoffen besteht ein Risiko, dass durch Mutation oder durch 
Rekombination mit einem Wildtypvirus ein neues pathogenes Virus entstehen könnte. Auch 
die Unterscheidung zwischen Impfstämmen und Wildtypviren ist schwierig. VÄP hingegen 
sind weder infektiös noch replikationsfähig und bieten den Vorteil, ein bestimmtes Antigen in 
hoher Dichte auf ihrer Oberfläche zu präsentieren und dadurch eine Immunantwort 
hervorzurufen.  
 
In dieser Arbeit wurden VÄP basierend auf dem murinen Leukämievirus (MLV) verwendet. 
Die ILTV Glycoproteine gB, gC, gD und gJ wurden an die Transmembrandomäne des 
epidermalen Wachstumsfaktor-Rezeptors fusioniert. Dieser ermöglicht eine Inkorporation in 
die Plasmamembran und damit die Präsentation auf VÄP. Durch Transfektion von zwei 
Expressionsvektoren (1. ILTV Glykoprotein, 2. MLV gag) in 293T Zellen wurden die 
pseudotypisierten VÄP hergestellt und verschiedene Methoden zu deren Charakterisierung 
etabliert.  
 
Weitere Arbeiten werden zeigen, ob die VÄP einen ausreichenden Schutz gegen eine ILTV-
Infektion bieten. 
 
Stichworte: Virusähnliche Partikel, Infektiöse Laryngotracheitis, Impfstoff 
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2. Introduction 
2.1 General biology of infectious laryngotracheitis virus 
Infectious laryngotracheitis virus (ILTV) is classified as a member of the family 
Herpesviridae in the subfamily of Alphaherpesvirinae (Fig. 1). Besides the Psittacid 
herpesvirus 1 it is the only member of the genus Iltovirus. ILTV is taxonomically identified as 
Gallid herpesvirus 1 (GaHV-1) (Roizman, 1982). It is possible to distinguish several 
genetically different classes of ILTV by a combination of polymerase chain reaction (PCR) 
and restriction fragment length polymorphism (RFLP). Up to now, nine classes have been 
identified (Blacker et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Phylogenetic analysis of DNA polymerase sequences from different herpesvirus 
species. (Rose, 2005). Arrows indicate the two members of the genus Iltovirus. 
  
The ILTV genome is a linear double-stranded DNA molecule (Swayne et al., 2013). Early 
electron micrographs of GaHV-1 infected chicken embryo cells demonstrated the presence of 
nucleocapsids with icosahedral symmetry (Cruickshank et al., 1963; Watrach et al., 1963). 
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These nucleocapsids measure 80-100 nm in diameter. The whole virus particle with its 
irregular envelope, surrounding the nucleocapsid and the tegument proteins varies in diameter 
between 200-350 nm (Fuchs et al., 2007). The envelope has characteristic surface projections 
identified as surface glycoprotein spikes (Fuchs et al., 2007).  
 
Although not analysed in detail GaHV-1 seems to initiate infection like other herpesviruses 
(Fuchs et al., 2007) i. e., by attachment to its target cell followed by fusion of the viral 
envelope with the host cell plasma membrane. The nucleocapsid is released into the 
cytoplasm and transported to the nuclear membrane. Viral DNA is released from the 
nucleocapsid and migrates into the nucleus through nuclear pores. Transcription and 
replication of viral DNA occurs within the nucleus (Guo et al., 1993). Newly synthesized 
viral DNA is cleaved into unit lengths and encapsulated into nucleocapsids. These DNA-filled 
nucleocapsids acquire an envelope by migration through the inner lamellae of the nuclear 
membrane. Enveloped particles then migrate through the endoplasmic reticulum and 
accumulate within vacuoles in the cytoplasm and are finally released by cell lysis or by 
vacuolar membrane fusion and exocytosis (Guo et al., 1993; Mettenleiter et al., 2002). 
 
2.2 Infectious laryngotracheitis (ILT): hosts, clinical signs and relevance 
Chickens are the natural hosts of ILTV.  Since the early description of the disease, ILT virus 
infections have been reported in pheasants, pheasant-chicken crosses, peafowls and young 
turkeys (Crawshaw et al., 1982; Winterfield, & So, 1968). Subclinical infections with 
seroconversion were also reported in ducks (Yamada et al., 1980). 
 
Birds of all ages can be affected. The most characteristic signs of the disease can be observed 
as early as three weeks of age (Dufour-Zavala, 2008). Disease signs generally appear 6-14 
days following natural exposure (Jordan, 1966). Infected birds show dyspnea with 
expectoration of blood-stained mucus and moderate to severe conjunctivitis, respiratory rales, 
watery eyes, swelling of infraorbital sinuses, mucoid tracheitis and persistent nasal discharge. 
Furthermore, ILT leads to decreased egg production and reduced weight gain (Swayne et al., 
2013), which in turn results in significant economic losses in the poultry industry worldwide 
(Shan-Chia & Giambrone, 2012). Besides suffering of the animals, this is the main reason 
why ILT is a major threat for the poultry industry. 
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2.3 Prevention and control of ILTV infection  
In Switzerland, ILT is reckoned among the notifiable animal diseases. Since 1987 various 
outbreaks were reported.  Notably, most of them were registered in fancy fowl. Upon 
verification of infection the affected livestock has to be culled, because surviving animals are 
silent carriers of ILTV. The so-called latency is a characteristic of herpesviruses. ILTV 
resides in the trigeminal ganglion after acute infection (Williams et al., 1992). Certain stress 
inducing conditions can provoke the recurrence of virus shedding, which can result in the 
infection of so far healthy animals (Hughes et al., 1989). Since there is no treatment against 
ILT, the only way to prevent infection would be an efficient vaccination. But even though 
various vaccines have been developed, immunization is not allowed in Switzerland and the 
disease is mainly controlled by prevention through biological safety measures (Albicker-
Rippinger et al., 1998). However, in most parts of the world chickens are vaccinated which 
bares certain risks (see 2.3.2). 
 
2.3.1 ILT vaccines 
Shortly after ILT was first described in 1925 (May & Tittsler, 1925), immunization of 
chickens was achieved by inoculating birds with virulent virus via the cloaca (Brandly et al., 
1934). This is considered the first effective vaccine developed for a major avian viral disease 
(Guy & Garcia, 2008). Subsequently, attenuated live vaccines were developed by consecutive 
passages of virulent virus in cell cultures (tissue culture origin, TCO) (Gelenczei & Marti, 
1965) or in embryonated chicken eggs (chicken embryo origin, CEO) (Samberg et al., 1969). 
These vaccines confer a robust protection against ILT infection, but they also bear a risk of 
reversion to virulence (see 2.3.2).  
 
To improve safety of ILTV immunization, various viral vector vaccines have been developed 
during the last years. Now available are Innovax ILT® (Merck/ MSD Animal Health Intervet) 
and Vectormune® FP LT (Ceva, Lenexa, Kansas, USA). Innovax ILT® is based on a turkey 
herpes virus (HVT), which has been genetically modified to express ILT glycoproteins I and 
D. It is approved for in ovo administration of 18-day-old embryos as well as for subcutaneous 
application in day-old chickens. The immunity against ILT is supposed to last for at least 60 
weeks. Vectormune® FP LT is also a recombinant live virus based on a Fowl Pox virus, 
which has been genetically modified to express ILT glycoprotein B and the membrane protein 
UL34. The vaccine is approved for wing web application of eight-week-old chickens.  
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Two other methods for immunizing chickens against ILTV were published, but not further 
developed into commercial vaccines. One method relies on the intraperitoneal application of 
affinity purified ILTV glycoprotein B (gB) in four-week-old chickens. This approach resulted 
in a protection of 83% of the chickens, as determined by the absence of ILT antigen in the 
trachea (York & Fahey, 1991). The other published experimental vaccination is also based on 
the antigen gB, but in this case a bicistronic DNA vector encoding gB and interleukin 18 
(IL18) was administered into the muscle of three-week-old chickens. 80% of the challenged 
chickens didn’t show any clinical signs, and PCR for ILTV in tracheal swab was negative 
(Chen et al., 2010).   
 
2.3.2 Advantages and disadvantages of currently available ILT vaccines 
To date, the most common vaccines against ILT are attenuated live vaccines. They are easy to 
apply – usually via drinking water or coarse spray – and confer a robust protection. However, 
live vaccines can induce latent infections, and occasional virus shedding is possible. Because 
of their ability to replicate, attenuated live vaccines can revert to more virulent variants, which 
was already shown for CEO but not for TCO vaccines (Guy et al., 1991). Furthermore, 
recombination between vaccine- and wild-type-strains, or between various circulating vaccine 
strains was observed. The latter was shown for some viruses, which were isolated during ILT 
outbreaks in 2008 and 2009 in Australia. The respective isolates were assigned to the new 
classes 8 and 9 (Blacker et al., 2011). In a later study, it was shown that these two new classes 
emerged most likely through interspecies recombination between the co-circulating 
Australian-origin (Poulvac®Laryngo SA2 and A20, Pfizer) and European-origin 
(Nobilis®ILT, Serva strain, Intervet) vaccines (Lee et al., 2012). Even though such 
recombination events seem to be rare, they can result in a fitness-advantage and cause a 
serious threat for poultry.  
 
Another issue of attenuated live vaccines is the difficult differentiation between vaccine and 
field strains. To circumvent this issue, several approaches with genetically modified viruses 
were published. An early attempt focused on the thymidine kinase (TK), which is known to 
be a virulence factor in other herpesviruses. Upon deletion of the TK gene the mutant ILTV 
showed a reduced virulence and induced protection against virulent ILTV in vivo (Han et al., 
2002). Other ILTV mutants were generated by deletion of UL0, glycoprotein J (gJ/US5), 
UL47 or glycoprotein C (gC/UL44). Even though most of these mutations led to reduced 
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titers, none of them was essential for replication of the virus. In vivo experiments showed a 
lower pathogenicity of the deletion mutants, and a sufficient protection against infection with 
wild type strains (Veits at al., 2003; Fuchs et al., 2005; Helferich at al., 2007; Pavlova et al., 
2010). Furthermore, these mutant ILTVs enable a serological differentiation between 
vaccinated and infected birds.  
 
The so far safest vaccines are the recombinant vector vaccines. The big advantage is that they  
may not establish a latent infection. One of the commercially available vector vaccines is 
based on a turkey herpesvirus (Innovax ILT®) and is applicable by in ovo administration. The 
drawback of this vaccine is the limited protection effect. However, according to the 
manufacturer it should last for at least 60 weeks, which is sufficient for most commercial 
implementations. According to Vagnozzi and coworkers (2012) the protection achieved with 
Innovax ILT® is almost as good as with the attenuated live ILT vaccines. In contrast, the 
other recombinant vector vaccine, based on a fowlpox virus (Vectormune® FP LT), was less 
efficient.  Furthermore, it is only recommended for wing web application, which poses 
problems for mass application. Both vaccines have in common that they are based on 
replicating viral vectors. Even though both of them are considered as apathogenic for chicken, 
these are still replicating viruses and thus bear a certain risk of mutation and unforeseeable 
consequences.  
 
2.4 Virus-like particles (VLPs) 
In contrast to attenuated live vaccines, so called subunit vaccines (SUVs) only consist of 
specific components of a pathogen (Murray, 1988). Mainly surface proteins of various 
pathogens have been used for the development of SUVs. But compared to attenuated live 
vaccines, the immunogenicity of SUVs is usually much lower. To overcome this issue various 
application techniques have been used, e.g. administration of adjuvants, booster injections or 
high doses of SUVs. Another way to improve the low immunogenicity was the development 
of virus-like particles (VLPs). Structural proteins of viruses tend to self-assemble into 
particles that mimic the morphology of the cognate pathogen. As viruses, VLPs can be 
divided into two groups:  enveloped and non-enveloped VLPs. The later ones only consist of 
the viral components, which are sufficient to self-assemble into a particle. By fusion of the 
coding sequences of additional, e.g., immunogenic antigens to those of the self-assembling 
pathogen part, chimeric VLPs can be generated (Fig. 2A, 2C). Some non-enveloped VLP 
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vaccines are already licenced. Examples are GenHevac B®, Engerix-B®, and Recombivax 
H® (against hepatitis B virus; HBV) and Cervarix ® and Gardasil® (against human 
papilloma virus; HPV). Enveloped VLPs are more complex. Besides the viral core proteins 
they also contain envelope proteins, which are incorporated into the surrounding membrane. 
These incorporated envelope proteins can either be from the same or from a different 
pathogen than the core proteins (Fig. 2B, 2D). And since these envelope proteins do not need 
to be covalently fused to another viral protein, the enveloped VLPs provide more flexibility in 
terms of generating chimeric VLPs. Nevertheless, both kinds of VLPs display antigenic 
epitopes in a highly repetitive manner and thus are able to provoke a strong cellular and 
humoral immune response (Deml et al., 2005; Shen et al., 2013). Besides the display of a 
single type of antigen per VLP, it is also possible to mix different VLPs for vaccination or to 
display various antigens on a particular VLP. VLPs are considered as very safe, since they are 
non-infective and non-replicating. 
 
 
 
 
 
 
 
 
 
 
Figure 2: Types of virus-like particles (VLPs). (A) Unmodified non-enveloped or (B) 
enveloped VLPs. Modified VLPs for presentation of heterologous antigens achieved 
either by (C) fusion of the respective epitopes to the self-assembling viral proteins or 
by (D) incorporation of antigens into the particle surrounding membrane.   
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2.5 Antigen candidates for vaccination against ILTV 
Glycoproteins located on the virus surface are major targets for the natural immune response 
(Ghiasi et al., 1996; Kreijtz et al., 2011) and appear to be highly immunogenic antigens, 
capable of eliciting both humoral and cell mediated responses (York & Fahey, 1990). Thus, 
they are promising candidates for potential vaccination approaches.  
 
ILTV potentially encodes 12 glycoproteins, which are conserved among the 
alphaherpesviruses. But so far, only nine of them have been identified on the protein level. 
These are gB (Poulsen & Keeler, 1997), gC (Kingsley et al., 1994), gD, gE, gI (Pavlova et al., 
2013), gG (Kongsuwan et al., 1993), gJ (Fuchs et al., 2005), gM and gN (Fuchs et al., 2005). 
Four of them were chosen for the development of a new ILT vaccine and are described in 
more detail in the following section.  
 
2.5.1 Glycoprotein B (gB, UL27) 
This is the most highly conserved herpesvirus structural glycoprotein (Pereira, 1994). Its 
function in ILTV is not known but it seems to be part of the basic fusion machinery as it was 
shown for other alphaherpesvirus gB proteins and thus is important for cell entry (Cai et al., 
1988). gB is synthesized in the endoplasmatic reticulum where it forms a homodimer and 
subsequently gets transported to the Golgi apparatus where further modifications and 
proteolytic cleavage takes place (Poulsen & Keeler, 1997). In contrast to Poulsen & Keeler, 
(1997) findings, the protein interaction prediction of: www.uniprot.org states that ILTV gB 
forms homotrimers. This protein is one of the most promising antigen candidates for vaccine 
development, since gB from various other herpesviruses elicit humoral (Keller et al., 1984) as 
well as cell-mediated immune (CMI) responses (Zarling et al., 1986). Even though the avian 
immune system is not comparable with the mammalian system, there is evidence for the 
existence of a humoral as well as a CMI reaction (Kaiser, 2010). For protection against ILTV 
infection the CMI seems to be more important (Fahey et al., 1983; Fahey & York, 1990; 
Honda et al., 1994). So far, several vaccination approaches using gB as an antigen have been 
published, e.g. application of affinity purified glycoproteins (York & Fahey, 1991), 
administration of a bicistronic plasmid vector (Chen et al., 2010) and recombinant fowlpox 
virus or turkey herpesvirus both expressing gB (Tong et al., 2001; Esaki et al., 2013). 
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2.5.2 Glycoprotein C (gC, UL44) 
For most alphaherpesviruses gC is not needed for infection of cells in tissue culture (Robbins 
et al., 1986) but it was shown that virus binding is increased up to 10 fold in the presence of 
gC. This might be due to an interaction of this glycoprotein with heparan sulphate on the cell 
surface (Osterrieder, 1999; Mettenleiter, 1990). Beyond its role in virus attachment, gC is also 
supposed to be involved in virus egress (Schreurs et al., 1988). It plays a role as virulence 
factor (Moffat et al., 1998) linked to the fact that it binds to the complement component C3b 
resulting in immune-evasion (Friedman et al., 1984). ILTV gC was described the first time in 
1994. It shows low amino acid homology to other herpesvirus gC proteins and it does not 
contain a charged extracellular domain, which would mediate binding to surface 
proteoglycans (Kingsley et al., 1994). An ILTV gC deletion-mutant was tested for its 
pathogenicity in vivo. It was attenuated in chicken, but high doses still led to severe clinical 
signs in 21% of the infected birds (Pavlova et al., 2010). Promising vaccination approaches 
against infection were observed with bovine herpesvirus-1 in cattle and duck plague virus in 
ducks. In both studies, a DNA vaccine encoding the respective gC protein was used (Gupta et 
al., 2001; Lian et al., 2011). 
 
2.5.3 Glycoprotein D (gD, US6) 
This glycoprotein is present in most alphaherpesviruses except in varicella zoster virus (VZV) 
and Marek disease virus (MDV). In fact, MDV contains a gene encoding for gD but so far it 
was not detected on the protein level (Tan et al., 2001; Davison, 2010). In other herpesviruses 
it is necessary for cell binding. Two receptors have been identified that interact with gD. 
These are nectin-1 and herpesvirus entry mediator (HVEM) (Heldwein & Krummenacher, 
2008). gD might also trigger later steps in virus entry, that finally lead to membrane fusion 
(Lazear et al., 2012). ILTV gD is essential for virus replication and is supposed to act in virus 
binding and entry (Pavlova et al., 2013). HSV-1 gD was used as a recombinant expressed 
antigen in vaccination approaches using vaccinia virus as a vector since 1985. Immunized 
mice were protected against latent herpesvirus infection (Cremer et al., 1985). For vaccination 
against ILT, two approaches using gD have been published. Both used recombinant viruses 
expressing gD. One was based on turkey herpesvirus (HVT) and the other on Newcastle 
disease virus (NDV) (Gimeno et al., 2011; Zhao et al., 2014).  
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2.5.4 Glycoprotein J (gJ, US5) 
gJ is encoded within the unique short (US) genome region of ILTV. There are positional 
homologues in many other herpesviruses, but they hardly share any sequence homology. 
According to immunoelectron micrographs, the protein seems to be associated with the viral 
envelope (Veits, et al., 2003). Supporting these data, gJ exhibits characteristics of a 
membrane protein like N-glycosylation site as well as a membrane anchor signal sequence 
(Fuchs et al., 2005). But in contrast to many other envelope glycoproteins, gJ is unlikely 
involved in virus attachment or cell entry but is supposed to play a role during virus egress 
(Mundt et al., 2011). Even though gJ seems to be highly immunogenic, no neutralizing 
antibodies were detected so far. A gJ deletion mutant was used as a potential vaccine that 
would enable serological differentiation between the vaccine and field strains (Fuchs et al., 
2005).  
 
2.6  Aim of the study 
In the present work, we anticipated to develop a new ILT vaccine based on virus-like 
particles. Four ILTV glycoproteins (gB, gC, gD, gJ) should be displayed on the surface of 
VLPs which are derived from the moloney murine leukemia virus (MMLV) (Fig. 3). To 
achieve the incorporation of the glycoproteins, they were fused to the transmembrane domain 
of a growth factor which is incorporated into the plasma membrane and thus also into VLPs 
(Fig. 4). 
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Figure 3: Generation of virus-like particles (VLPs). Upper right: Scheme of a wild type 
 MLV particle. Upper left: Scheme of the viral genome. Middle left: Genome part of 
MLV sufficient for the formation of VLPs (structural protein gag). Lower part: Upon 
transfection of the gag encoding plasmid (pHit60) into the producer cell line 293T, 
virus-like particles will be secreted into the supernatant.  
 
 
 
Figure 4: Generation of ILTV glycoprotein displaying VLPs. Upper part: Scheme of the 
relevant plasmid parts encoding for the ILTV glycoprotein, the transmembrane domain  
(platelet derived growthfactor receptor transmembrane domain; PDGFR TM) and the 
tags (HA, His, myc), as well as the VLP structural protein gag encoding plasmid pHit60. 
Lower part: Upon transfection of both plasmids into 293T cells the VLPs with the 
incorporated ILTV glycoproteins will be released into the cell supernatant.  
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3. Materials and Methods 
3.1 Cloning of ILTV glycoproteins into an expression vector 
To facilitate the display of the ILTV glycoproteins on the VLP surface, they need to be 
incorporated into the plasma membrane of the VLP producer cell. To achieve this, the 
respective glycoprotein sequences and fragments thereof were cloned into the plasmid 
pDisplayTM.  This plasmid is an expression vector that already contains the murine Ig-κ chain 
leader sequence, which will direct the fusion protein to the secretory pathway. Furthermore, it 
contains the platelet derived growth factor receptor (PDGFR) transmembrane domain (TM), 
which will anchor the protein to the plasma membrane, displaying the protein on the cell 
surface. For easy detection by Western blot (WB) or immunofluorescence (IF) the influenza 
virus hemagglutinin (HA) and myc epitopes are encoded on the plasmid as well (a map of the 
plasmid is shown in Fig. 6). ILTV glycoproteins also contain one or more TM domains. The 
putative TM domains were excluded from cloning. Only the N-terminal parts that are 
displayed on the surface of ILTV particles were used for cloning. In Fig. 5 a scheme of the 
relevant part of pDisplay as well as the various ILTV glycoprotein fragments are shown. 
 
 
Figure 5: Scheme of pDisplay and the ILTV glycoproteins A. A scheme of the relevant part of 
the cloning vector pDisplay. B-E. Upper row: Scheme of the respective ILTV 
glycoprotein containing one or two putative transmembrane (TM) domains. Lower rows: 
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Position of the various fragments of the glycoproteins that were to be expressed. The 
numbers behind the respective glycoprotein fragment correspond to the number of amino 
acids.  
The oligonucleotide sequences used for cloning are listed in Table 1 and the reagents used in 
Table 2. 
 
 
Oligo-
nucleotide 
name 
Sequence Rest-
riction 
site 
gB1(+)  GTATGGCCCAGCCGGCCCACCATCATCATCACCACGCTAGCGCACAA
TCCTACATCGCCGTG 
SfiI 
gB231(-) GACTCCGCGGCCTTCCCTCGATTTCCACAACACAGTCGACCGATGTAG SacII 
gB232(+)  GTAGGGCCCAGCCGGCCCACCATCATCATCACCACGCTAGCGCATAT
CTACAGGCTAGATCTG 
SfiI 
gB464(+) 
 
GTATGGCCCAGCCGGCCCACCATCATCATCACCACGCTAGCGCATTT
GCCATGTTACAATTTG 
SfiI 
gB722_Sal(-) GACTGTCGACCCTTCCCTCGATCTTTCCTACTTCTCCAAGAGTGTTG SalI 
gC1(+) GTATGGCCCAGCCGGCCCACCATCATCATCACCACGCTAGCGCACAG
CATCAGAGTACTGCG 
SfiI 
gC385_Sal(-) GACTGTCGACCCTTCCCTCGATGACTGCGGGGAATCCTTGCCGCATTG SalI 
gD1_Bgl(+) GTAGAGATCTCACCATCATCATCACCACGCTAGCGCAGACCGCCATTT
ATTTTTG 
BglII 
gD307_Sal(-) GACTGTCGACCCTTCCCTCGATGGGGAGGGCGGCAGGATTTTC SalI 
gD349_Sal(-) GACTGTCGACCCTTCCCTCGATGGAGACGGCATTAGAACTTTTAGTAG
TC 
SalI 
gJ1(+) GTATGGCCCAGCCGGCCCACCATCATCATCACCACGCTAGCGCAGGG
ACAATGTTAGTGTTG 
SfiI 
gJ959(-) GACTCCGCGGCCTTCCCTCGATGAGTGAATACAGCTGCGCCTGAGCA
G 
SacII 
gJ959_Pst(-) GACTCTGCAGCCTTCCCTCGATGAGTGAATACAGCTGCGCCTGAGCA
G 
PstI 
gJ520(-) GACTCCGCGGCCTTCCCTCGATGGTCTGGGCAGGTGCCTCGGTTTCTG SacII 
gJ521_Bgl(+) GTAGAGATCTCACCATCATCATCACCACGCTAGCGCACCGAGCACGA
TACCCGAG 
BglII 
 
Table 1: Oligonucleotides used for cloning. Bold: restriction sites, underlined: 6x His tag 
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Product Source 
10x loading-Buffer for DNA-Agarose Gels 1.5 g Ficoll 400, 2 ml EDTA, 0.5 
ml bromophenol blue, at 7 ml 
H2O 
1Kb Plus DNA Ladder www.lifetechnologies.com,  
Cat. No. 10488-085 
Agarose, LE, Analytical Grade www.promega.de, Cat. No. 
V3121 
dNTPs (10 mM) www.qiagen.com, Cat. No. 
201900 
DreamTaq DNA Polymerase www.thermoscientificbio.com,  
Cat. No. EP0701 
Ethidiumbromid (EtBr) 98% www.carlroth.com, Cat. No. 
2218.1 
ILTV DNA  
Strain A489 
Federal Research Institute for 
Animal Health, Friedrich-
Loeffler-Institut, Greifswald-Insel 
Riems, Germany 
LB-Agar Plates (incl. 100 µg/ ml Ampicillin) Difco TM  www.bd.com, Cat. No. 215331 
NucleoSpin® Gel and PCR Clean-up  www.mn-net.com, Cat. No. 
740609.10 
pDgB700 www.lifetechnologies.com 
Phusion high fidelity polymerase www.neb.com, Cat. No. M0530S 
Plasmid pDisplay (see Fig. 6) www.lifetechnologies.com,  
Cat. No. V660-20 
pHit60 Soneoka et al., 1995 
Primer  www.microsynth.ch 
QIAGEN Plasmid Maxi/Mini Kit www.qiagen.com,  
Cat. Nos. 12123 and 12125 
Restriction endonucleases: BamHI, BglI, EcoRI, 
EcoRV, HindIII, PstI, SacII, SfiI, SspI 
www.neb.com 
S.O.C Medium www.lifetechnologies.com,  
Cat. No. 15544-034 
T4 DNA ligase  www. neb.com, Cat. No. M0202S 
TAE Buffer  0.4 M TRIS, 0.1 M Na2EDTA 
pH 8.0, 0.2 M Glacial acetic acid 
TOP10 chemically competent E. coli www.lifetechnologies.com,  
Cat. No. C4040-03 
TOPO® XL PCR Cloning Kit www.lifetechnologies.com,  
Cat. No. K4750-10 
 
Table 2: Reagents used for cloning 
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Figure 6: Scheme of pDisplayTM. The complete sequence is available on the web site: 
www.lifetechnologies.com. 
 
3.1.1 Amplification of ILTV glycoprotein sequences 
PCR run conditions and the standard PCR reaction mixture are shown in Table 3. The PCR 
was run in a thermal cycler 2720 (Applied Biosystems, Foster City, CA, USA). The PCR 
products were purified with NucleoSpin® Gel and PCR Clean-up kit and digested with the 
respective restriction endonucleases (Table 1) followed by a second purification. 
pDisplay was digested with the respective endonucleases. 
 
A    B  
98°C 1’  ILTV DNA 50 ng 
98°C 0.5’ 
25x 
Dream Taq buffer 5 µl 
45-52°C 0.5’ dNTPs (10mM) 2 µl 
72°C 1.5’-3’ Primer (+) (10 µM) 2 µl 
72°C 10’  Primer (-) (10 µM) 2 µl 
4°C ∞  Dream Taq 0.5 µl 
 Add H2O to total 50 µl 
 
Table 3 A: Cycler program used to amplify the ILTV glycoprotein sequences. Annealing 
temperature was adjusted to primer length and the elongation time to the length of the 
PCR product. B: Standard PCR preparation 
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3.1.2 Ligation 
The ligation mixtures of prepared pDisplay vectors with selected digested PCR products as 
inserts are shown in Table 4. The molecular ratio of vector backbone to insert was 1:3. 
Ligation mixtures were prepared as indicated in table 4 and incubated over night at 16°C or 
10 minutes at 22°C. Preparations without insert, one with and one without T4 ligase, served 
as negative controls. 
 
 
 neg. 1 neg. 2 pDgB231 pDgB232-
722 
pDgB464-
722 
pDgC385 
vector 50 ng 50 ng 50 ng 50 ng 50 ng 50 ng 
insert --------- --------- 20 ng 42 ng 22 ng 33 ng 
T4 lig. buffer 1 µl 1 µl 1 µl 1 µl 1 µl 1 µl 
T4 ligase 0.5 µl --------- 0.5 µl 0.5 µl 0.5 µl 0.5 µl 
Add H2O to a 
total volume 
10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 
 
 
 
 pDgD307 pDgD348 pDgJ520 pDgJ521-959 pDgJ959 
vector  50 ng 50 ng 50 ng 50 ng 50 ng 
insert 28 ng 30 ng 44 ng 37 ng 81 ng 
T4 lig. buffer 1 µl 1 µl 1 µl 1 µl 1 µl 
T4 ligase 0.5 µl 0.5 µl 0.5 µl 0.5 µl 0.5 µl 
Add H2O to a 
total volume 
10 µl 10 µl 10 µl 10 µl 10 µl 
 
Table 4: Ligation mixtures for ligation of ILTV glycoprotein gene sequences into the 
pDisplay vector. 
 
3.1.3 Transformation of chemically competent E.coli   
A 100 µl aliquot of chemically competent bacteria was thawed on ice. The whole ligation mix 
was added and kept on ice for 45 min. Bacteria were heat-shocked for 45 seconds at 42°C. 
LB-medium without antibiotics was added and bacteria were allowed to recover for 1 h at 
37°C. Bacteria were pelleted and supernatant was removed. The pellet was resuspended in 
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100 µl LB-medium and subsequently plated on, ampicillin-containing plates. Plates were 
incubated over night at 37°C. 
 
3.1.4 Isolation of DNA from competent E. coli 
To isolate plasmid DNA from bacteria the respective bacterial colony was transferred from 
the agar plate into 5 ml LB-medium containing ampicillin (100µg/ml). Bacteria were allowed 
to grow at 37°C for about 12 hours while shaking. DNA was either extracted directly from the 
5 ml culture using the Qiagen Plasmid Mini Kit, or bacteria were further cultivated over night 
in 200 ml antibiotic containing LB-medium at 37°C while shaking and plasmid DNA was 
extracted using the Qiagen Plasmid Maxi Kit. Concentration and purity of the isolated 
plasmid DNA was determined using the NanoDrop spectrophotometer (Witec AG, Littau, 
Switzerland) 
 
3.1.5 Colony PCR and control restrictions enzyme analyses 
To check the cloning product for the correct insertion of the ILTV glycoprotein sequence, 
whole bacterial colonies were subjected to a PCR. Primers are listed in Table 5. RedTaq® 
ReadyMixTM and the same cycler program was used as mentioned in 3.1.1 except that the 
initial step at 98°C was prolonged to 10 minutes. Plasmids were isolated from bacterial 
colonies that were positive in the PCR and were digested with the endonucleases listed in 
Table 5. Clones that showed the predicted band pattern upon separation on an agarose gel, 
were sent for sequencing. 
 
 
 pDgB231 pDgB232-722 pDgB464-722 pDgC385 
Primer (+) gB1(+) gB232(+) gB464(+) gC1(+) 
Primer (-) gB231(-) gB722_Sal(-) gB722_Sal(-) gC385_Sal(-) 
Restriction 
endonucleases HindIII ScaI SspI ScaI 
Fragment size 5300 bp 
743 bp 
4055 bp 
2756 bp 
4042 bp 
1121 bp 
4729 bp 
1776 bp 
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 pDgD307 pDgD348 pDgJ520 pDgJ521-959 pDgJ959 
Primer (+) gD1_Bgl(+) gD1(+) gJ1(+) gJ521_Bgl(+) gJ1(+) 
Primer (-) gD307_Sal(-) gD348(-) gJ520(-) gJ959_Pst(-) gJ959(-) 
Restriction 
endonucleases Scal BamHI ScaI EcoRI EcoRV 
Fragment size 4179 bp 
2086 bp 
5227 bp 
1161 bp 
3715 bp 
3195 bp 
5884 bp 
783 bp 
5556 bp 
2671 bp 
 
 Table 5: Primers and restriction endonucleases used for verification of the cloning products 
 
3.2 Tissue culture 
 
Product Source  
Cell line: 293 T (human, embryonal kidney) www.dsmz.de,  
Cat. No. ACC-635 
Cell line: LMH (chicken hepatocellular epithelial cell line) www.cell-lines-service.de 
DMEM (Dulbecco’s modified eagle’s medium – high 
glucose) 
www.sigmaaldrich.com, Cat. 
No. D6429 
DPBS (10X), no calcium, no magnesium (Gibco®) www.lifetechnologies.com, 
Cat. No. 14190-094 
Dulbecco’s Phosphate buffered saline (PBS) www.sigmaaldrich.com, 
Cat. No. D8537 
Fetal Bovine Serum, Mesenchymal Cell Qualified, US 
Origin (Gibco®) 
www.lifetechnologies.com, 
Cat. No. 10270 
Opti-MEM® Reduced Serum Medium (Gibco®) www.lifetechnologies.com, 
Cat. No. 11058-021 
RIPA Buffer www.sigmaaldrich.com, 
Cat. No. SC 24948 
TransIT®-2020 Transfection Reagent www.mirusbio.com, 
Cat. No. MIR 5400 
Trypsin-EDTA solution (Gibco®) www.lifetechnologies.com, 
Cat. No. T 3924 
Waymouth’s Medium (Gibco®) www.lifetechnologies.com, 
Cat. No. 31220-023 
 
Table 6: Reagents used for tissue culture 
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3.2.1 Cultivation of cells 
 
LMH cells (Kawaguchi et al., 1987) were grown in Waymouth’s Medium supplemented with 
10% fetal bovine serum (FBS) and cultivated in a humidified incubator at 38°C with 5% CO2. 
Cells were subcultivated twice a week in a ratio of 1:5 or 1:6. 
 
293 T cells were grown in DMEM supplemented with 10 % FBS and cultivated in a 
humidified  incubator at 38°C with 5% CO2. Cells were  subcultivated twice a week in a ratio 
of 1:10. 
3.2.2 Transfection 
 
For immunofluorescence (IF) cells were seeded on cover slips in 24-well plates (LMH 1x 
105/0.5 ml, 293T 8x 104/0.5 ml). For preparation of lysates for Western blot analysis or 
generation of VLP-containing supernatants, cells were seeded into 6-well plates (LMH 7x 
105/ ml, 293T 5x 105/ ml). 24 h later, cells were transfected using the TransIT-2020 
transfection reagent according to the manufacturer protocol. After overnight incubation the 
medium was carefully changed against medium without FBS. As controls, 293T cells were 
transfected with pHit60 alone or with one of the ILTV glycoprotein expression constructs 
alone. 48 h after transfection supernatants (SN) were collected, filtered through a 0,45 µm 
filter, and concentrated by low speed centrifugation (2600x g, 4°C, 24h). Pellets were re-
suspended in PBS and used for further analysis.  
 
In the SN of cells that have been transfected with pHit60 and a glycoprotein expression 
plasmid, both should be detectable by Western blot analysis. In the SN of cells that have been 
transfected with pHit60 alone, only gag should be recognizable and in SN of cells that have 
been transfected only with one of the glycoprotein expression construct, nothing should be 
detectable (Fig. 7: A, B, C).  
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Figure 7: Scheme of the possible outcome after transfection of different plasmids. A: 
Transfection of pHit60 (encoding MLV gag) and an expression plasmid for one of the 
ILTV glycoproteins (pDgB700, pDgC385, pDgD307, pDgJ959). B: Transfection of 
pHit60 alone. C: Transfection of the ILTV glycoprotein expression plasmid alone.  
 
3.2.3 Particle collection and cell lysis 
 
48 h after transfection, VLP-containing supernatants were collected as described in 3.2.2., 
filtered through a 0.45 µm pore size filter and concentrated by low speed centrifugation at 
2600x g at 4°C for 24 h. The supernatant was discarded and each pellet was resuspended in 
100 µl PBS. The cells were carefully washed once with PBS. 1 ml fresh PBS was added per 
well, cells were scraped of and transferred to an Eppendorf tube. Cells were pelleted by 
centrifugation (10’, 10.000x g, 4°C) and subsequently lysed using RIPA lysis buffer.  
 
3.3 Immunofluorescence  
 
Product Source 
Anti-HA.11 mouse monoclonal 
antibody clone16B12 
www.covance.com,  
Cat. No. MMS-01R 
Bovine serum albumin (BSA) www.amresco-inc.com, Cat. No. 8076.3 
DAPI www.lifetechnologies.com, Cat. No. D3571 
Donkey anti-mouse IgG-Alexa 
Fluor® 488 antibody  
www.lifetechnologies.com,  
Cat. No. A-21202 
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Product Source 
Fluorescent mounting medium www.dako.com, Cat. No. S3023 
Goat serum www.lifetechnologies.com, Cat. No. 16210-064 
Paraformaldehyde www.carlroth.com, Cat. No. 0335.1 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4 
RPMI-1640 medium www.sigmaaldrich.com, Cat. No. R7388 
Triton X-100 www.carlroth.com, Cat. No. 3051.3 
 
Table 7: Reagents used for immunofluorescence 
 
Transfected cells were not fixed with paraformaldehyde (PFA) to prevent permeabilization of 
the plasma membrane, but were cooled down to 4°C to minimize their metabolic activity. 
Living cells were incubated for 30 minutes at 4°C with a mouse antibody against the HA-tag 
(diluted 1:300 in RPMI/ 2%BSA). Afterwards, cells were washed and fixed with 3% 
paraformaldehyde. Upon three times washing with PBS coverslips were incubated with the 
Alexa Fluor® 488-coupled secondary antibody (diluted 1:1000 in PBS/ 10% goat serum) and 
DAPI for 45 minutes at room temperature. After three times washing with PBS coverslips 
were mounted on glass slides and used for imaging.   
 
3.4 Indirect ELISA 
 
Product Source 
Anti-c-Myc-tag rabbit polyclonal 
antibody 
www.genscript.com,  
Cat. No. A00172-100 
Anti-HA.11 mouse monoclonal 
antibody clone16B12 
www.covance.com,  
Cat. No. MMS-01R 
Anti-His mouse monoclonal 
antibody  
www.signalchem.com,  
Cat. No. H99-63R-25 
Anti-ILTV gB goat antiserum Ceva Biomune, K.Moore Dorsey, Lenexa, KS, USA 
Anti-ILTV gC mouse antiserum Federal Research Institute for Animal Health, 
Friedrich-Loeffler-Institut, Greifswald-Insel Riems, 
Germany 
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Product Source 
Anti-ILTV gD rabbit antiserum Federal Research Institute for Animal Health, 
Friedrich-Loeffler-Institut, Greifswald-Insel Riems, 
Germany 
Anti-ILTV gJ mouse antiserum Federal Research Institute for Animal Health, 
Friedrich-Loeffler-Institut, Greifswald-Insel Riems, 
Germany 
Blocking Buffer 5% BSA, 0.1% Tween 20 in PBS 
Coating buffer 50mM NaHCO3 pH 9.6 
Donkey anti-goat IgG-HRP 
antibody 
www.scbt.com, Cat. No. sc-2020  
Goat anti-mouse IgG-HRP 
antibody 
www.scbt.com, Cat. No. sc-2354 
Goat anti-rabbit IgG-HRP antibody www.cellsignal.com, Cat. No. 7074 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4 
PBST 0.05% Tween 20 in PBS 
Stop buffer 3% HCl 
TMB www.genscript.com, Cat. No. M00078 
Triton X-100  www.carlroth.com, Cat. No. 3051.3 
 
Table 8: Reagents and antibodies used for ELISA 
 
Concentrated VLPs were diluted in coating puffer. Triton X-100 was added to a final 
concentration of 0.5%. 90 µl of each sample was pipetted into a 96 well microtiter plate. After 
overnight incubation at 4°C, the supernatant was discarded, and the plate was incubated with 
blocking buffer. After 1 hour at room temperature the supernatant was discarded. Incubation 
with the first antibody was performed for 1 h at room temperature. After three times washing, 
incubation with the horseradish peroxidase (HRP) coupled secondary antibody was performed 
for 1 h at room temperature. The plate was washed three times and 100 µl TMB reagent was 
added per well. After 30 minutes at room temperature, the reaction was stopped by adding 
100 µl stop buffer. The absorbance was measured at 450 nm on a microplate reader Multiskan 
Ex Primary EIA V.2.3. (Thermo Fisher Scientific, Waltham, MA, USA).  
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3.5 Western Blot 
 
Product  Source 
6x Loading buffer (Lämmli) 60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% 
β-mercaptoethanol, 0.01% bromophenol blue 
8% SDS polyacrylamide gel 6.7 ml 30% Acrylamid, 6.5 ml lower Tris pH 8.8, 
15 µl TEMED, 200 µl APS 10% 
Anti-HA.11 mouse monoclonal 
antibody clone 16B12 
www.covance.com,  
Cat. No. MMS-101R 
Anti-MLV Gag (p30) polyclonal 
rabbit antibody 
www.icosagen.com,  
Cat. No. A1-910-100 
Blotting buffer Cell-buffer, 15% Methanol 
Cell-buffer 25 mM Tris-Hydroxy-Methyl-Amoniomethan, 
192mM Glycine 
Enhanced chemiluminescence (ECL) 
reagent 
0.1 M Tris-HCL(pH 6.8), 125 mg Luminol sodium 
salt, 35% H2O2, Para-Hydroxy Coumarin Acide, 
Dimethyl Sulfoxide (DMSO) 
Fuji Medical X-ray Film 100 NIF www.fujifilm.com 
Goat anti-mouse IgG-HRP antibody www.scbt.com, Cat. No. sc-2005 
Goat anti-rabbit IgG-HRP antibody www.cellsignal.com, Cat. No. 7074 
Non-fat dry milk in TBS Migros 
Ripa-Lysis-buffer  www.piercenet.com, Cat. No. SC 24948 
Running-buffer Cell-buffer, SDS 10% 
TBS buffer 19.8 mM Tris, 500 mM NaCl 
TTBS buffer TBS buffer, 0.05% Tween 20 
Whatman® Protran® nitrocellulose 
membranes, pore size 0.45 µm 
www.sigmaaldrich.com,  
Cat. No. 10.401196 
 
Table 9: Reagents and antibodies used for Western blotting 
 
Gel electrophoresis was done in the Mini Protean system (BioRad). Lysates (see 3.2.3) were 
loaded on 8% SDS polyacrylamide gels and separation was performed following the standard 
SDS PAGE protocol (Laemmli, 1970). For blotting, filter papers and nitrocellulose 
membranes were equilibrated in transfer buffer. Transfer was done for 1.5 hours at 20V at 
room temperature. Membranes were blocked in 5% non-fat dry milk in Tris-Buffered Saline 
(TBS) for 1 h at room temperature. Incubation with the primary antibody was done over night 
 
 
 
 28 
at 4 °C under constant shaking. Membranes were washed three times with TTBS for 10 
minutes each. Incubation with the secondary antibody (coupled to horseradish peroxidase) 
was done for 1 hour at room temperature. After washing three times with TTBS for 10 
minutes each, detection was done by incubation with ECL reagent for 5 minutes. For 
visualization, membranes were exposed to Fuji Medical X-ray Film 100 NIF and films were 
developed using the Agfa Curix 60 (Schenk AG, Hettlingen, Switzerland). 
 
3.6 Immuno gold labelling and electron microscopy 
 
Product Source 
Anti-ILTV gJ mouse 
antiserum 
Federal Research Institute for Animal Health, Friedrich-
Loeffler-Institut, Greifswald-Insel Riems, Germany 
Bovine serum albumin (BSA) www.amresco-inc.com, Cat. No. 9048-46-8 
Goat anti-mouse IgG gold 10 
nm 
www.sigmaaldrich.com,  
Cat. No. G7652 
Goat serum www.lifetechnologies.com, Cat. No. 50197Z 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4 
Uranylacetate acid www.polysciences.com, Cat. No. 21447-25 
 
Table 10: Reagents and antibodies used for immuno gold labelling  
 
Concentrated VLPs were spotted on copper grids precoated with parlodion/carbon. After 
adsorption for 2 minutes, excess buffer was soaked off and grids were washed four times with 
PBS/10% goat serum for 1 minute. Grids were incubated with the anti-ILTV gJ antibody, 
diluted 1:50 in PBS/1% goat serum for 30 minutes at room temperature. Grids were washed 
with PBS/10% goat serum 5 times for 2 minutes and subsequently incubated with the 
secondary gold-conjugated antibody diluted 1:50 in PBS/0.1% BSA for 30 minutes at room 
temperature. After washing twice with PBS/0.1% BSA and 4 times with H2O for 1 minute, 
grids were treated with 3% uranyl acetate for 20 seconds. Excess fluid was removed and grids 
were air dried before imaging with the transmission electron microscope (TEM). 
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4. Results 
4.1 Cloning of ILTV-glycoprotein-expression constructs 
4.1.1 Control endonuclease digestions of the final cloning products 
 
 
 
Figure 8: Restriction pattern of the different ILTV glycoprotein expression plasmids. The 
final cloning products (indicated above the picture) were cleaved with the respective 
restriction endonucleases and the fragments were separated by gel electrophoresis in a 
1% agarose gel supplemented with ethidium bromide. Samples that are marked with 
an arrow (↑) were sent for sequencing and the one marked with an asterisk () were 
proven to be correct and were used for further experiments. 
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4.2 Expression of ILTV glycoproteins  
4.2.1 Intracellular expression of ILTV glycoproteins  
 
 
 
 
Figure 9: Western blot analysis of the expression of ILTV glycoproteins in 293T cells using 
anti HA-antibodies. A: Western blot of 293T cells transfected with pDgB231, 
pDgB232-722, pDgB464-722, pDgC385, pDgD348, pDgJ959, pDgJ520, pDgJ521-
959. B: Western blot of 293T cells transfected with the plasmids that were used for 
further experiments (pDgB700, pDgC385, pDgD307, pDgJ959). 
 
 
All proteins could be detected (Fig. 9). Most samples showed more than one band. But in all 
cases the most prominent band corresponded with the predicted molecular weight. For further 
experiments only constructs that contained the whole surface part were used. These are 
gB700, gC385, gD307, gJ959 (Fig. 5). Even though gD307 is 41 amino acids (aa) shorter 
than gD348, it was decided to use this construct, since gD348 is not expressed on the cell 
surface (data not shown).  
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4.2.2 Surface expression of ILTV glycoproteins  
 
Figure 10: Immunofluorescence analysis of the surface expression of ILTV glycoproteins. 
Upper row: DAPI. Lower row: anti-HA antibody.  
 
The four glycoproteins gB700, gC385, gD307, gJ959 were detected on the cell surface of 
transfected 293T cells.  
 
4.3 Expression of pseudotyped virus-like particles (VLPs) 
4.3.1  VLP detection by Western blot analysis 
 
 
 
 
Figure 11: Western blot of SN of transfected 293T cells. Cells were transfected either with a 
plasmid encoding for the MLV gag protein and/or with an expression construct for the 
ILTV glycoprotein.  VLPs were detected by using an antibody against MLV gag. 
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MLV gag was detectable in SNs of cells that have been transfected with pHit60, 
indicating the formation and secretion of VLPs.  
 
 
Figure 12: Western blot of SN of transfected 293T cells. Cells were transfected either with a 
plasmid encoding for the MLV gag protein and/or with an expression construct for the 
ILTV glycoprotein.  The ILTV glycoproteins were detected by using an antibody 
against the HA-tag.  
  
Only in SN of cells that have been transfected with pHit60 and pDgC385, gDC385 was 
detected by Western blot. In the case of gD307 or gJ959, also in SN of cells that have been 
transfected only with the ILTV glycoprotein expression constructs, a slight band is visible. 
Strong bands appeared for SN of cells that have been transfected exclusively with pDgB700. 
The bands in the samples which were transfected with pDgB700 and pHit60 were only 
slightly more intense (Fig. 12). 
4.3.2 VLP detection by ELISA  
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Figure 13: ELISA from supernatants containing VLPs . 293 T cells were transfected with 
pHit60 alone. Detection with an antibody against MLV gag.  
 
Using the MLV gag antibody enabled the detection of VLPs in concentrated SN of 
transfected cells. This allows the relative quantification of VLPs.  
 
 
Figure 14: ELISA from supernatants containing gD307 pseudotyped VLPs. 293 T cells were 
transfected with pHit60 and pDgD307. Detection with an antibody against ILTV gD. 
 
gD307 was detected in SN of VLP-gD307 but also in SN of cells that were transfected with 
pDgD307 alone.  
 
Figure 15: ELISA from supernatants containing gJ959 pseudotyped VLPs. 293 T cells were 
transfected with pHit60 and pDgJ959. Detection with an antibody against ILTV gJ. 
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gJ959 was detected in the SN of 293T cells that have been transfected with pHit60 and 
pDgJ595.  
ILTV glycoproteins C and B could not be detected in ELISA (data not shown).  
 
4.3.3 VLP detection by electron microscopy  
 
Using an antibody against ILTV gJ, gJ959 was detected in close proximity to the VLPs, 
indicating a successful incorporation of the ILTV glycoprotein into the MLV derived VLP.  
 
 
Figure 16: Electron micrographs of immunogold labelled VLPs pseudotyped with gJ959.  
A. SN of 293T cells only transfected with pHit60 (VLP). B, C. SN of 293T cells that 
have been transfected with pHit60 and pDgJ959 (VLP-gJ959). Arrowheads indicate 
immunogold particles (scale bar 100 nm). 
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5.  Discussion 
In this study the basis for a new vaccination approach against ILT in chickens was 
established. Virus-like particles (VLPs) based on the murine leukemia virus (MLV), were 
generated that display various glycoproteins of ILTV on their surface.  
 
Expression of all generated ILTV encoding plasmids was verified by Western blotting. All 
constructs of this study could be detected. Most of the glycoproteins differed slightly from the 
predicted size and/or showed additional bands, which might be due to the existence of various 
splice and cleavage products or modifications of the respective proteins. Poulsen & Keeler, 
(1997) made similar observations in their study. They infected chicken embryonic kidney 
(CEK) cells with the USDA challenge strain of ILTV. Upon immunoprecipitation with an 
ILTV gB antiserum, samples were analysed by polyacrylamide gel electrophoresis and 
revealed two bands with a size of 110 kDa and 58 kDa. Further analyses involving various 
glycosylation inhibitors showed band shifts to reduced sizes, which led to the final conclusion 
that  gB is expressed as a precursor that will assemble into homodimers or -trimers. On its 
way through the Golgi it is modified by several glycosylations and finally is proteolytically 
cleaved to form two disulphide-linked entities, which have the same molecular mass but 
differ in their modifications (Poulsen & Keeler, 1997).  Our results are not directly 
comparable to this study. Instead of infecting chicken cells with the USDA challenge strain, 
we used expression constructs encoding various parts of gB and transfected these into the 
human cell line 293T. The closest to the wild type gB is gB700, which contains the first 700 
N-terminal amino acids (aa) of in total 882 aa. The predicted size is 98 kDa. We detected two 
major bands with sizes of about 100 kDa and 70 kDa and two minor bands with about 65 kDa 
and 50 kDa. These multiple bands are most likely also due to  proteolytical cleavage and 
glycosylation processes. 
 
The construct gB231, encompassing the first 231 aa, revealed two major bands of about 
65 kDa and 28 kDa. The predicted size was 33 kDa.  The detected 65 kDa band might be due 
to a disulfide bond linked version of the small protein. The construct gB232-722 has a 
predicted size of 57 kDa. In our Western blot a band of about 60 kDa was detected. For the 
construct gB464-722, which has a predicted size of 37 kDa, two bands were detected. One of 
about 35 kDa and one with 26 kDa.  
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In a study published by Pavlova and colleagues Western blot analysis of ILTV-A489 infected 
CEK cells revealed a single 60 kDa band when using a gC specific antibody. In our study, 
Western blot analysis of 293T cells transfected with gC385 showed two bands of about 52 
kDa and 60 kDa. That the bands were larger than the predicted weight of 43 kDa could be 
explained by N-glycosylations like it was described for ILTV gC before (Fuchs et al., 2005). 
The appearance of two bands cannot be explained. In this study, an antibody detecting the 
HA-tag was used but in further experiments the antibody against ILTV gC will be applied. 
 
Another study by Pavlova and colleagues characterized ILTV gD. Upon infection of CEK 
cells with ILTV-A489 and Western blot analysis, they detected bands of 70 kDa and 65 kDa. 
In virus particles only the 70 kDa version could be detected, indicating that this is the mature 
and functional version of gD. The 65 kDa form of gD was speculated to be an immature, 
degraded, or differentially processed functional form of gD. The size difference compared to 
the calculated mass of 48.5 kDa was explained by possible phosphorylations, since no 
glycosylations were detected (Pavlova et al., 2013). In this study gD348 was transfected into 
293T cells and lysates were used for Western blotting. One major band of about 40 kDa was 
detected and two minor bands of 30 kDa and 16 kDa. In later experiments it was shown that 
this construct was not expressed on the cell surface. This might be due to an incomplete 
deletion of the gD transmembrane domain or signal peptide, and thus a possible retention in 
the endoplasmatic reticulum (data not shown).  The construct gD307 only contained the first 
307 aa of in total 376 aa. In Western blot analysis of transfected 293T cells three dominant 
bands with sizes of about 49 kDa, 40 kDa and 30 kDa were detected and a less pronounced 
band of about 16 kDa.  
 
ILTV gJ is reported to have two splice variants. Fuchs and colleagues (2005) cloned the full 
genomic gJ gene and the cDNA fragment of the spliced gJ mRNA species. Upon transfection 
into LMH cells and Western blotting, the spiced gJ revealed a single band at 85 kDa. The full-
length construct showed a similar pattern like in cells infected with the wild type ILTV A489 
strain, namely four bands with sizes of 200 kDa, 160 kDa, 115 kDa and 85 kDa.  Even though 
the calculated mass would be 106.5 kDa. By using different glycosylation inhibitors, they 
could show that gJ contains N- and O-glycosylations (Fuchs et al., 2005). In our study, three 
different gJ expression constructs were generated. The one closest to the wild type is gJ959 
containing the first 959 aa of in total 985 aa. Upon expression in 293T cells, the Western blot 
analysis revealed three bands with sizes of about 100 kDa, 85 kDa and 65 kDa. A fourth 
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larger band was not detected, but this might be due to the use of 10% SDS polyacrylamide 
gel. To get a better resolution for bigger proteins, gels with less polyacrylamide will be 
applied in further experiments. gJ520 only contains the first 520 aa. Since this constructs lack 
the splice acceptor site, no splice variants could be detected in Western blot analysis. Only a 
single band of about 70 kDa was visible. The difference to the predicted size of 63 kDa might 
be due to glycosylations. For gJ521-959 various bands were detected. This was not expected, 
since this construct contains the splice acceptor but not the splice donor site. Our hypothesis 
is that this part of the protein forms dimers or is modified in other ways.  
 
For further characterisations, only the glycoprotein-constructs gB700, gC385, gD307 and 
gJ959 were used. These ones only lack their own TM domain and the C-terminal part, but 
contain the whole N-terminal region. To test whether the glycoproteins are expressed on the 
cell surface, immunofluorescence of transfected and non-permeabilized cells was performed. 
Upon transfection of 293T cells with the glycoprotein expression constructs alone or in 
combination with the packaging construct encoding for gag, the SN were analysed by 
Western blotting to check the presence of VLPs with incorporated glycoproteins. All tested 
glycoproteins could be detected. This implies a successful incorporation of the glycoprotein 
into the VLP. If transfected alone, a very dim band for gD and gJ was visible, which might be 
due to a few non-incorporated glycoproteins. In contrast, if gB was transfected alone, the 
detected bands were only slightly less pronounced compared to samples of SN of cells 
transfected with gB and gag. This indicates the presence of free gB in the supernatant. A 
possible cleavage by extracellular proteases is likely to be excluded since addition of protease 
inhibitors did not reduce the detected protein in the supernatant (data not shown). 
 
For quantification of the VLPs enzyme-linked immunosorbent assays (ELISAs) were 
established. Detection of gag was successful using a polyclonal gag antibody. Unfortunately, 
the only glycoproteins that could be detected in ELISA were gD and gJ. Detection was 
possible with specific antibodies against the respective proteins. The gD ELISA did also 
support the results obtained by Western blot. Traces of gD were detected in SN of cells that 
were transfected with gD alone, indicating the presence of non-VLP associated glycoproteins. 
gB and gC were neither recognized by specific antibodies nor by antibodies against the HA-, 
His-, or Myc-tag (data not shown). Thus further improvements need to be done, to enable 
detection of gB and gC in ELISA. The quantification of VLPs by gag ELISA is no suitable 
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measure to evaluate the effectiveness of vaccine production, since it would be more important 
to know the amount of antigen displayed at the VLP surface.   
 
A third way of characterising the VLPs was immunogold labelling followed by imaging under 
an electron microscope. So far, only VLPs pseudotyped with ILTV gJ were successfully 
labelled and imaged.  They were stained with an antibody against ILTV gJ, which in turn was 
recognized by a secondary antibody coupled to a 10 nm gold particle. The microscopy clearly 
showed gold particles in close proximity to the VLP, indicating incorporation into the VLP-
surrounding membrane.  The antibodies against the various tags (HA, His, Myc) did not lead 
to the recognition of the corresponding glycoproteins. Thus, staining conditions will be 
improved in further experiments and specific antibodies against gB, gC, and gD will be 
tested. 
 
In conclusion the basis for the establishment of a new ILT vaccine was developed. ILTV 
glycoproteins can be incorporated into MLV VLPs. Furthermore, various assays were 
developed for characterisation and quality control of the generated VLPs. Nevertheless, 
before ending up with the final VLPs that can be used in immunization experiments, several 
optimizations need to be done.  So far, VLPs were generated by transient transfection of the 
plasmid pHit60 into 293T cells. pHit60 encodes the MLV gag protein but in addition also the 
retroviral enzymes (reverse transciptase, integrase, protease). For safety considerations it is 
desirable to use minimal parts of the parental virus. Since the viral enzymes are not needed 
for the generation of VLPs, an expression-construct for gag alone will be cloned. This can be 
used to establish a stable cell line for large scale VLP production. Furthermore, VLPs will be 
generated in chicken LMH cells instead of human 293T cells. This should prevent unwanted 
immune reactions to the cell derived membrane surrounding the VLPs. For quantification of 
VLPs respectively the displayed glycoproteins, a reference is required. Thus, the 
glycoproteins will be purified from transfected cells and used as a standard in ELISA. 
Moreover, ELISAs for the detection of gB and gC have to be optimized, e.g. by testing 
different antibodies and/or modifying the conditions (buffers, incubation times, blocking 
reagent, etc.), and before using the pseudotyped VLPs in vivo they need to be purified.  
 
 
 
 
 
 39 
6. References 
 
Albicker-Rippinger, P. and Hoop, R. (1998). Die Infektiöse Laryngotracheitis (ILT) in der 
Schweiz: Aktueller Stand und Gedanken zu zukünftigen Bekämpfungsmöglichkeiten. 
Schweizer Archiv für Tierheilkunde, 140, 65-69. 
 
Blacker, H. P., Kirkpatrick, N. C., Rubite, A., O’Rourke, D., & Noormohammadi, A. H. 
(2011). Epidemiology of recent outbreaks of infectious laryngotracheitis in poultry in 
Australia. Australian Veterinary Journal, 89(3), 89–94.  
 
Brandly, C.A. & Bushnell, L.D. (1934). A report of some investigations of infectious 
laryngotracheitis. Poultry Science, 13, 212-217. 
 
Cai, W. H., Gu, B., & Person, S. (1988). Type 1 in viral entry and cell fusion. Role of 
Glycoprotein B of Herpes Simplex Virus Type Entry and Cell Fusion. Journal of Virology, 
62(8). 2596-2604. 
 
Chen, H.-Y., Zhao, L., Wei, Z.-Y., Cui, B.-A., Wang, Z.-Y., Li, X.-S., & Liu, J.-P. (2010). 
Enhancement of the immunogenicity of an infectious laryngotracheitis virus DNA vaccine by 
a bicistronic plasmid encoding glycoprotein B and interleukin-18. Antiviral Research, 87(2), 
235–241.  
 
Crawshaw, G. J., & Boycott, B. R. (1982). Infectious laryngotracheitis in peafowl and 
pheasants. Avian Diseases, 26(2), 397–401. 
 
Cremer, K. J., Mackett, M., Wohlenberg, C., Notkins, A. L., & Moss, B. (1985). Vaccinia 
virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent 
herpes in mice. Science (New York, N.Y.), 228(4700), 737–740.  
 
Cruickshank, J.G., D.M. Berry, & B. Hay. (1963). The fine structure of infectious 
laryngotracheitis virus. Virology,  20, 376-378. 
 
 
 
 40 
Davison, S., Gingerich, E. N., Casavant, S., & Eckroade, R. J. (2009). Evaluation of the 
Efficacy of a Live Fowlpox-Vectored Infectious Laryngotracheitis/Avian Encephalomyelitis 
Vaccine Against ILT Viral Challenge. Avian Diseases, 50, 50-54. 
 
Davison, A. J. (2010). Herpesvirus systematics. Veterinary Microbiology, 143(1), 52–69. 
 
Deml, L., Speth, C., Dierich, M. P., Wolf, H., & Wagner, R. (2005). Recombinant HIV-1 
Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. 
Molecular Immunology, 42(2), 259–277.  
 
Dufour-Zavala, L. (2008). Epizootiology of infectious laryngotracheitis and presentation of an 
industry control program. Avian Diseases, 52(1), 1–7.  
 
Esaki, M., Noland, L., Eddins, T., Godoy, A., Saeki, S., Saitoh, S., & Saitoh, B. S. (2013). 
Safety and Efficacy of a Turkey Herpesvirus Vector Laryngotracheitis Vaccine for Chickens. 
Avian Diseases, 57(2), 192–198. 
 
Fahey, K. J., & York, J. J. (1990). The role of mucosal antibody in immunity to infectious 
laryngotracheitis virus in chickens. Journal of General Virology, 71(10), 2401–2405.  
 
Fahey, K. J., Bagust, T. J., & York, J. J. (1983). Laryngotracheitis herpesvirus infection in the 
chicken: the role of humoral antibody in immunity to a graded challenge infection. Avian 
Pathology,12(4), 505–514.  
 
Friedman, H. M., Cohen, G. H., Eisenberg, R. J., Seidel, C. A., & Cines, D. B. (1984). 
Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement 
component on infected cells. Nature, 309(5969), 633–635.  
 
Fuchs, W., J. Veits, D. Helferich, H. Granzow, J.P. Teifke, & T.C. Mettenleiter. (2007). 
Molecular biology of avian infectious laryngotracheitis virus. Veterinary Research, 38, 261-
279. 
 
 
 
 
 41 
Fuchs, W., Wiesner, D., Veits, J., Teifke, J. P., & Mettenleiter, T. C. (2005). In vitro and in 
vivo relevance of infectious laryngotracheitis virus gJ proteins that are expressed from spliced 
and nonspliced mRNAs. Journal of Virology, 79(2), 705–716.  
 
Gelenczei, E.F. & Marty, E.W. (1965). Strain stability and immunologic characteristics of a 
tissue-culture-modified infectious laryngotracheitis virus. Avian Diseases, 14(1), 44-56. 
 
Ghiasi, H., Nesburn, A. B., & Wechsler, S. L. (1996). Vaccination with a cocktail of seven 
recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more 
efficiently than vaccination with any individual glycoprotein. Vaccine, 14(2), 107–112.  
 
Gimeno, I. M., Cortes, A. L., Guy, J. S., Turpin, E., & Williams, C. (2011). Replication of 
recombinant herpesvirus of turkey expressing genes of infectious laryngotracheitis virus in 
specific pathogen free and broiler chickens following in ovo and subcutaneous vaccination. 
Avian Pathology, 40(4), 395–403. 
 
Guo, P., E. Scholz, J. Turek, R. Nodgreen, R, & B. Maloney. (1993) Assembly pathway of 
avian infectious laryngotracheitis virus. American Journal of Veterinary Research, 
54, 2031-2039. 
 
Gupta, P. K., Saini, M., Gupta, L. K., Rao, V. D. P., Bandyopadhyay, S. K., Butchaiah, G., & 
Garg, S. K. (2001). Induction of immune responses in cattle with a DNA vaccine encoding 
glycoprotein C of bovine herpesvirus-1. Veterinary Microbiology, 78(4), 293–305. 
 
Guy J.S. & Garcia M. (2008). Laryngotracheitis, p.121-134. In: Saif Y.M., Barnes H.J., 
Glisson J.R., Fadly A.M., McDougald L.R. & Swayne D.E. (Eds), Diseases of Poultry. 12th 
ed. Iowa State Press, Ames.  
 
Guy JS, Barnes HJ, & Smith L. (1991). Increased virulence of modified-live infectious 
laryngotracheitis vaccine virus following bird-to-bird passage. Avian Diseases, 35(2), 348-
355.  
 
 
 
 
 
 42 
Han, M.G., Kweon, C. H., Mo, I. P., & Kim, S. J. (2002). Pathogenicity and vaccine efficacy 
of a thymidine kinase gene deleted infectious laryngotracheitis virus expressing the green 
fluorescent protein gene. Archives of Virology, 147: 1017-1031. 
 
Heldwein, E. E., & Krummenacher, C. (2008). Entry of herpesviruses into mammalian cells. 
Cellular and Molecular Life Sciences: CMLS, 65(11), 1653–68.  
 
Helferich, D., Veits, J., Teifke, J. P., Mettenleiter, T. C., & Fuchs, W. (2007). The UL47 gene 
of avian infectious laryngotracheitis virus is not essential for in vitro replication but is 
relevant for virulence in chickens. The Journal of General Virology, 88(3), 732–742.  
 
Honda, T., Taneno, A., Sakai, E., Yamada, S., & Takahashi, E. (1994). Immune response and 
in vivo distribution of the virus in chickens inoculated with the cell-associated vaccine of 
attenuated infectious laryngotracheitis (ILT) virus. The Journal of Veterinary Medical Science 
/ the Japanese Society of Veterinary Science, 56(4), 691–695.  
 
Hughes C.S., Gaskell R.M., Jones R.C., Bradbury J.M., & Jordan F.T.W.,(1989). Effects 
of  certain stress factors on the re-excretion of infectious laryngotracheitis virus from latently 
infected carrier birds, Research in Veterinary Science, 46, 274–276.  
 
Jordan, F.T. (1966). A review of the literature on infectious laryngotracheitis (ILT). Avian 
Diseases, 10, 1-26. 
 
Kaiser, P. (2010). Advances in avian immunology-prospects for disease control: a review. 
Avian Pathology, 39(5), 309–324. 
 
Kawaguchi, T., Nomura, K., Hirayama, Y., & Kitagawa, T. (1987). Establishment and 
characterization of a chicken hepatocellular carcinoma cell line, LMH. Cancer Research, 47, 
4460-4464. 
 
Keller, P. M., Neff, B. J., & Ellis, R. W. (1984). Three major glycoprotein genes of varicella-
zoster virus whose products have neutralization epitopes. Journal of Virology, 52(1), 293–
297. 
 
 
 
 43 
 
Kingsley, D. H., Hazel, J. W., & Keeler, C. L. (1994). Identification and characterization of 
the infectious laryngotracheitis virus glycoprotein C gene. Virology, 203(2), 336–43. 
 
Kongsuwan, K., Johnson, M. A., Prideaux, C. T., & Sheppard, M. (1993). Identification of an 
infectious laryngotracheitis virus gene encoding an immunogenic protein with a predicted 
M(r) of 32 kilodaltons. Virus Research, 29(2), 125–140. 
 
Kreijtz, J. H. C. M., Fouchier, R. A. M., & Rimmelzwaan, G. F. (2011). Immune responses to 
influenza virus infection. Virus Research, 162(1-2), 19–30. 
 
Laemmli, U. K. (1970), Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature, 227, 680–685. 
 
Lazear, E., Whitbeck, J. C., Ponce-de-Leon, M., Cairns, T. M., Willis, S. H., Zuo, Y.,  & 
Eisenberg, R. J. (2012). Antibody-induced conformational changes in herpes simplex virus 
glycoprotein gD reveal new targets for virus neutralization. Journal of Virology, 86(3), 1563–
1576.  
 
Lee, S.-W., Markham, P. F., Coppo, M. J. C., Legione, A. R., Markham, J. F., 
Noormohammadi, A. H., & Devlin, J. M. (2012). Attenuated vaccines can recombine to form 
virulent field viruses. Science (New York, N.Y.), 337(6091), 188. 
 
Lian, B., Cheng, A., Wang, M., Zhu, D., Luo, Q., Jia, R., & Chen, X. (2011). Induction of 
immune responses in ducks with a DNA vaccine encoding duck plague virus glycoprotein C. 
Virology Journal, 8(1), 214,1-8. 
 
May H. & Tittsler R., (1925) Tracheolaryngitis in poultry. Journal of the American Veterinary 
Medical Association, 67, 229 -231. 
Mettenleiter, T. C. (2002). Herpesvirus Assembly and Egress. Journal of Virology, 76(4), 
1537–1547. 
 
 
 
 
 44 
Mettenleiter, T. C. (1990). Interaction of Glycoprotein glll with a Cellular Heparinlike 
Substance Mediates Adsorption of Pseudorabies Virus. Journal of Virology, 64(1), 278-286. 
 
Moffat, J. F., Zerboni, L., Kinchington, P. R., Grose C., Kaneshima, H. & Arvin, A. M., 
(1998). Attenuation of the vaccine Oka strain of varicella-zoster virus and role of 
glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. Journal of 
Virology, 72(2), 965-974. 
 
Mundt, A., Mundt, E., & Garcia, M. (2011). Generation of a glycoprotein J deletion mutant of 
infectious laryngotracheitis virus (ILTV) as potential vaccine for DIVA approach. In 
Proceedings of the 2010 AAAP Annual Meeting (pp. 2954) Atlanta GA, USA. 
 
Murray, K. (1988). Application of recombinant DNA techniques in the development of viral 
vaccines. Vaccine, 6(2), 164–174. 
 
Osterrieder, N. (1999). Construction and characterization of an equine herpesvirus 1 
glycoprotein C negative mutant. Virus Research, 59(2), 165–177. 
 
Pavlova, S., Veits, J., Mettenleiter, T. C., & Fuchs, W. (2013). Identification and Functional 
Analysis of Membrane Proteins gD, gE, gI, and pUS9 of Infectious Laryngotracheitis Virus. 
Avian Diseases, 57, 416–426. 
 
Pavlova S., Veits J., Blohm U., Maresch C., Mettenleiter T.C., & Fuchs W. (2010). In vitro 
and in vivo characterization of glycoprotein C-deleted infectious laryngotracheitis virus. 
Journal of General Virology, 91(4), 847-857. 
 
Pereira, L. (1994). Function of glycoprotein B homologues of the family herpesviridae. 
Infectious Agents and Disease, 3(1), 9–28. 
Poulsen, D., & Keeler, C. J. (1997). Characterization of the assembly and processing of 
infectious laryngotracheitis virus glycoprotein B. Journal of General Virology, 78(11), 2945–
2951. 
 
 
 
 
 45 
Robbins, A. K., Watson, R. J., Whealy, M. E., & Hays, W. W., L.W. Enquist. (1986). 
Characterization of a pseudorabies virus glycoprotein gene with homology to herpes simplex 
virus type 1 and type 2 glycoprotein C. Journal of Virology, 58(2), 339-347.  
 
Roizman, B. (1982). The family Herpesviridae: General description, taxonomy and 
classification. In:B. Roizman (ed). The Herpesviruses, Vol. I. Plenum Press, New York. pp. 
1-23. 
 
Rose, T. M. (2005). CODEHOP-mediated PCR - a powerful technique for the identification 
and characterization of viral genomes. Virology Journal, 2(1), 20, 1-24. 
 
Samberg, Y., Cuperstein, E., Bendheim, U., & Aronovici, I. (1969). The development of a 
vaccine against avian infectious laryngotracheitis. IV. Immunization of chickens with a 
modified laryngotracheitis vaccine in the drinking water. Avian Diseases, 15(2), 413–417. 
 
Schreurs, C., Mettenleiter, T. C., Zuckermann, F., Sugg, N., & Ben-Porat, T. (1988). 
Glycoprotein gIII of pseudorabies virus is multifunctional. Journal of Virology, 62(7), 2251–
2257. 
 
Shan-Chia, O., & Joseph J. Giambrone. (2012). Infectious laryngotracheitis virus in chickens. 
World journal of virology, 5, 142-149. 
 
Shen, H., Xue, C., Lv, L., Wang, W., Liu, Q., Liu, K., & Cao, Y. (2013). Assembly and 
immunological properties of a bivalent virus-like particle (VLP) for avian influenza and 
Newcastle disease. Virus Research, 178(2), 430–436. 
 
Soneoka,Y. Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M., 
& Kingsman, A. J. (1995). A transient three-plasmid expression system for the production of 
high titer retroviral vectors. Nucleic Acids Research, 23(4), 628-633. 
 
Swayne D.E., Garcia M., Spatz S., & Guy J.S. (2013). Diseases of Poultry 13th edition, 161-
179. 
 
 
 
 
 46 
Tan, X., Brunovskis, P., & Velicer, L. F. (2001). Transcriptional Analysis of Marek ’ s 
Disease Virus Glycoprotein D , I , and E Genes: gD Expression Is Undetectable in Cell 
Culture. Journal of Virology, 75(5), 2067–2075.  
 
Tong, G. Z., Zhang, S. J., Wang, L., Qiu, H. J., Wang, Y. F., & Wang, M. (2001). Protection 
of chickens from infectious laryngotracheitis with a recombinant fowlpox virus expressing 
glycoprotein B of infectious laryngotracheitis virus. Avian Pathology, 30(2), 143–148. 
 
Vagnozzi, A., Zavala, G., Riblet, S. M., Mundt, A., & García, M. (2012). Protection induced 
by commercially available live-attenuated and recombinant viral vector vaccines against 
infectious laryngotracheitis virus in broiler chickens. Avian Pathology, 41(1), 21–31. 
 
Veits, J., Köllner, B., Teifke, J. P., Granzow, H., Mettenleiter, T. C., & Fuchs, W. (2003). 
Isolation and characterization of monoclonal antibodies against structural proteins of 
infectious laryngotracheitis virus.Avian Diseases, 74 (2), 330–342. 
 
Watrach, A.M., Hanson L.E., & Watrach M.A. (1963). The structure of infectious 
laryngotracheitis Virus. Virology, 21, 601-608. 
 
Williams, R. A., Bennett, M., Bradbury, J. M., Gaskell, R. M., Jones, R. C., & Jordan, F. T. 
(1992). Demonstration of sites of latency of infectious laryngotracheitis virus using the 
polymerase chain reaction. The Journal of General Virology, 73 (9), 2415–2420.  
 
Winterfield, R. W., & So, I. G. (1968). Susceptibility of turkeys to infectious 
laryngotracheitis. Avian Diseases, 12(1), 191–202. 
 
Yamada, S., Matsuo, K., Fukuda, T., & Uchinuno, Y. (1980). Susceptibility of ducks to the 
virus of infectious laryngotracheitis. Avian Diseases, 24(4), 930–938. 
 
York, J., & Fahey, K. (1991). Vaccination with affinity-purified glycoproteins protects 
chickens against infectious laryngotracheitis herpesvirus. Avian Pathology, 20(4), 693–704. 
 
 
 
 
 47 
York, J., & Fahey, K. (1990). Humoral and cell-mediated immune responses to the 
glycoproteins of infectious laryngotracheitis herpesvirus. Archives of Virology, 115(3-4), 
289–297. 
 
Zarling, J. M., Moran, P. A., Burke, R. L., Pachl, C., Berman, P. W., & Lasky, L. A. (1986). 
Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. 
Recognition and activation by cloned glycoproteins gB and gD. Journal of Immunology, 
136(12), 4669–73. 
 
Zhao, W., Spatz, S., Zhang, Z., Wen, G., Garcia, M., Zsak, L., & Yu, Q. (2014). Newcastle 
disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) 
glycoproteins gB and gD protect chickens against ILTV and NDV challenges. Journal of 
Virology, 88(15), 8397–8406.  
 
 
 
 
 
Danksagung 
Herrn Professor Dr. Richard Hoop danke ich für die Betreuung und die Überlassung des 
Themas. 
 
Bei Frau PD Dr. Monika Engels bedanke ich mich für die gewissenhafte Durchsicht und 
Prüfung dieses Manuskripts als Korreferentin. 
 
Dr. Nina Wolfrum danke ich für die wissenschaftliche Betreuung, die kompetente 
Beantwortung all meiner Fragen und die gewissenhafte Durchsicht, Ergänzung und 
Bearbeitung meines Manuskripts.  
 
Dr. Kurt Tobler danke ich für die grosse fachliche Unterstützung und die Mut machenden 
Gespräche, die mir sehr geholfen haben. 
 
Allen Mitarbeiterinnen der Abteilung für Geflügelkrankheiten insbesondere Brigitte Sigrist 
möchte ich ein herzliches Dankeschön sagen für die freundliche Aufnahme in ihrem Team.   
 
Ein ganz besonderer Dank geht auch an Dr. Andrea Schedle, Dr. med. Rosmarie Jungbluth, 
Dr. med. Angela Rotthoff-Nolte,  Dr. Corinna Scheel, Prof. Dr. med. Krassen Nedeltchev und 
Elisabeth Moser, die immer an mich glaubten und mit mir auch in schwierigen Zeiten einen 
machbaren Weg suchten, selbst wenn ich schon aufgegeben hatte. Die konstruktiven 
Gespräche haben mir sehr geholfen. 
 
Natürlich bedanke ich mich auch bei Dr. med. vet. Beat Stähli, der mit konstantem Druck 
dafür sorgte, dass ich dran blieb und mir doch immer wieder die Möglichkeit gab „Praxisluft“ 
zu schnuppern und mich daran erinnerte warum ich diese Arbeit auf mich nahm. 
 
Danke auch an meine Freunde, die mich ertragen und getragen haben. Corinne Scheuchzer, 
die mir immer zugehört hat und sich super um Felino, mein Pferd, gekümmert hat, wenn ich 
mal wieder keine Zeit hatte. Vera Morf-Tobler, die immer ein offenes Ohr hatte und für mich 
da war. Nina Morf und Anegreth Buff, die mir ihre Englischkenntnisse zur Verfügung gestellt 
haben. Alex Sieber, mein guter alter Freund auf den immer Verlass ist, Ruth Hunkeler-
 
 
 
Wittleder, die mir bei so manchem Mittagessen im Irchel wieder Mut machte und Meta 
Schwendimann, die immer an mich geglaubt hat.  
 
Und zu guter Letzt ein Danke an meine tierischen Freunde, die  so manche Laune von mir 
ertragen mussten und ihre Liebe zu mir immer wieder von neuem bewiesen haben.  
 
  
 
 
 
Curriculum Vitae 
 
Name, Vorname:  Zbinden Jeannette 
 
Geburtsdatum:  01.07.1971 
 
Geburtsort:   Zürich 
 
Nationalität:   Schweiz 
 
Heimatorte:   Zürich und Wahlern (BE) 
 
 
 
 
April 1978 – April 1984 Primarschule, Zürich-Affoltern 
 
April 1984 – April 1987 Sekundarschule, Zürich-Affoltern 
 
Mai 1987 – Jan. 1991  Arztgehilfinnenschule Juventus 
 
Feb. 2002 – Mai 2005 Kantonale Maturitätsschule für Erwachsene, Zürich 
 
 
Aug. 2005 – Okt. 2011 Studium Veterinärmedizin, Vetsuisse-Fakultät Universität 
Zürich, Schweiz  
 
Jan. 2012 – Dez. 2012 Assistentin Kleintierpraxis ACR, Winterthur 
 
Jan. 2013 – April 2015 Dissertation, Institut für Veterinärbakteriologie, Abteilung für 
Geflügelkrankheiten, Vetsuisse-Fakultät Universität Zürich 
